Business Context and Reporting Period
Company: TAO Synergies Inc. (formerly Synaptogenix, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Reporting Date: March 31, 2026
TAO Synergies Inc. underwent a significant strategic pivot in 2025. Originally a biopharmaceutical company focused on developing Bryostatin-1 for Alzheimer's disease, the Company launched a differentiated cryptocurrency treasury strategy in June 2025. This strategy involves accumulating and staking TAO, the native token of the Bittensor decentralized AI blockchain, to generate yield and capital appreciation. The Company changed its name and ticker symbol (from SNPX to TAOX) effective June 26, 2025. While the biopharmaceutical division remains, clinical trials for Multiple Sclerosis were terminated in late 2024, and the Alzheimer's program is in an evaluation phase.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenues | $299,061 | $0 |
| Net Loss | $(28,737,448) | $(12,768,549) |
| Operating Expenses | $9,346,218 | $6,810,732 |
| Other Loss, Net | $(19,690,291) | $(5,957,817) |
| Cash and Cash Equivalents (End of Period) | $5,497,671 | $17,656,221 |
| Digital Assets (TAO) Fair Value | $17,927,183 | $0 |
| Total Assets | $25,835,021 | $17,733,779 |
| Working Capital | $23,564,919 | $16,706,587 |
Note: The Net Loss for 2025 includes an unrealized loss on digital assets of approximately $10.5 million and a change in fair value of warrant liabilities of approximately $12.4 million.
Material Changes vs. Prior Period
- Revenue Generation: The Company generated $299,061 in revenue from TAO staking in 2025, compared to zero revenue in 2024.
- Asset Composition: Digital assets (TAO) now comprise a significant portion of the balance sheet ($17.9 million), representing a shift from a cash-heavy balance sheet in 2024 ($17.7 million cash).
- Expense Structure: General and Administrative (G&A) expenses increased by 73.1% to $9.0 million, driven by non-cash stock-based compensation ($2.2 million) and legal fees related to restructuring. Research and Development (R&D) expenses decreased by 79.8% to $322,225 due to the termination of the Cleveland Clinic MS trial and reduced clinical activity.
- Financing Activity: The Company raised capital through Series D and Series E private placements of convertible preferred stock and warrant exercises, generating approximately $23.1 million in net cash from financing activities.
- Unrealized Losses: The "Other Loss, Net" line item expanded significantly due to the volatility of TAO holdings and the revaluation of complex warrant and derivative liabilities.
Guidance, Outlook, and Risks
Outlook and Strategy: Management intends to continue accumulating TAO, targeting the allocation of 75% to 100% of "excess cash" (cash beyond 1.5–2.0 years of operating needs) to the asset. The Company views TAO as a long-term holding and does not currently hedge its exposure. The biopharmaceutical division remains in a holding pattern, with management evaluating next steps for the Bryostatin-1 program.
Material Risks:
- Crypto Volatility: The Company's financial condition is heavily dependent on the price of TAO. A significant decline could materially impair assets and liquidity.
- Regulatory Uncertainty: Risks exist regarding the classification of TAO as a security, which could impose significant compliance burdens or force a change in strategy.
- Operational Risks: Reliance on third-party custodians (BitGo) and validators (Yuma, tao5) introduces counterparty and cybersecurity risks.
- Liquidity: While the Company projects sufficient liquidity for 12 months, it may require additional financing to pursue its TAO accumulation goals or advance biopharmaceutical trials.
- Internal Controls: Management identified material weaknesses in internal control over financial reporting, including inadequate segregation of duties and ineffective IT general controls.
Investor Verification Checklist
- TAO Holdings Valuation: Verify the current market price of TAO and the Company's specific token count (approx. 81,319 tokens as of Dec 31, 2025) to assess current unrealized gains/losses.
- Convertible Preferred Stock Terms: Review the redemption schedules and dividend rates for Series D (5% dividend) and Series E (7% dividend) preferred stock, as these represent significant cash obligations.
- Warrant Liability Reclassification: Confirm the status of warrant liabilities (Series C and D) which were reclassified to equity following amendments, and monitor for any remaining derivative liabilities.
- Biopharmaceutical Status: Verify the current status of the Bryostatin-1 program and any new clinical trial announcements, as the Company has no near-term revenue from this segment.
- Internal Control Remediation: Monitor subsequent filings for updates on the remediation of identified material weaknesses in internal controls.